



## CASUISTIC PAPER

Michał Osuchowski<sup>1(ABCGF)</sup>, Dorota Bartusik-Aebisher<sup>2(DFG)</sup>, Ewa Kaznowska<sup>1(DFG)</sup>,  
David Aebisher<sup>3(DFG)</sup>

# Fibromatosis-like spindle-cell metaplastic carcinoma of the breast – a case report

<sup>1</sup> Department of Morphological Sciences, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland

<sup>2</sup> Department of Biochemistry and General Chemistry, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland

<sup>3</sup> Department of Photomedicine and Physical Chemistry, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland

## ABSTRACT

**Introduction.** Metaplastic breast carcinoma is expressing epithelial and/or mesenchymal tissue within the same tumor.

**Aim.** The aim of this study is to evaluate metaplastic breast carcinoma in a case report and literature review.

**Description of the case.** The presented case describes metaplastic carcinoma of the breast in 65 years old female patient.

**Conclusion.** Fibromatosis-cell metaplastic carcinoma of the breast presents a particularly large diagnostic challenge. Malignant variants of this disease have been described in the literature.

**Keywords.** breast cancer, fibromatosis, metaplastic breast carcinoma

## Introduction

Metaplastic carcinoma of the breast is a heterogeneous group of malignant tumors. It is composed of neoplastic cells that exhibit epithelial and/or mesenchymal differentiation. This form of breast cancer may be aggressive and accounts for less than 1% of all breast cancer diagnoses.<sup>1</sup> Fibromatosis-like spindle-cell metaplastic carcinoma (FLSpCC) is a variant of metaplastic carcinoma that needs to be distinguished from other cancers due to its favorable outcome.<sup>2</sup> It rarely metastasizes to axillary lymph nodes and has very low potential for distant metastases.<sup>3</sup> On the other

hand it presents a high risk of local recurrence.<sup>4</sup> FLSpCC cannot be reliably diagnosed by Ultrasound or Magnetic Resonance Imaging alone and therefore requires histological examination.<sup>5</sup> It also requires a different therapeutic approach than other metaplastic carcinomas of the breast.<sup>6</sup>

## Aim

This study covers histopathological examination in order to diagnose metaplastic carcinoma. We studied histopathology in order to assess the degree of cytologic and histologic correlation in the cytology based diagnosis.

**Corresponding author:** Michał Osuchowski, e-mail: [michal126@interia.pl](mailto:michal126@interia.pl)

**Participation of co-authors:** A – Author of the concept and objectives of paper; B – collection of data; C – implementation of research; D – elaborate, analysis and interpretation of data; E – statistical analysis; F – preparation of a manuscript; G – working out the literature; H – obtaining funds


Received: 19.09.2020 | Accepted: 6.12.2020

Publication date: March 2021

### Description of the case


65 years old female patient has been admitted to an Oncological Surgery Clinic because of a palpable right breast tumor. In the performed ultrasound examination, the lesion was identified and defined as grade 4a on the BIRADS scale. No enlarged axillary lymph nodes were visualized. The patient was qualified for surgical treatment.

Postoperative material was sent to our Pathology Department for final diagnosis. On gross examination tumor was white, solid, with well-defined borders. It measured 55 x 42 x 30 mm. On microscopic examination the lesion appeared deceptively benign. It consisted of bland spindle cells in a prominent collagenous stroma with infiltrative borders (Figure 1).



**Fig. 1.** Bland spindle cells in prominent collagenous stroma with infiltrative borders (H&E, 40X)


On high magnification low-grade atypical cytologic features including hyperchromasia, polymorphism and irregular contours of cell nuclei could be identified (Figure 2).




**Fig. 2.** Low-grade atypical cytologic features (H&E, 200X)

After further examination the tumor proved to be biphasic. Positive immunohistochemical stains for Smooth Muscle Actin (SMA) (Figure 3) and p63 (Fig-


ure 4), suggested myoepithelial differentiation, while stains such as CK7 (Figure 5) pointed to epithelial differentiation.



**Fig. 3.** Positive SMA immunohistochemical stain (200X)



**Fig. 4.** Positive p63 immunohistochemical stain (100X)




**Fig. 5.** Positive CK7 immunohistochemical stain (100X)


At least one cytokeratin stain must be positive in order to diagnose metaplastic carcinoma. In the absence of any keratin a different diagnosis should be made.<sup>7,8</sup> Stains for estrogen receptor (Figure 6), progesterone re-




ceptor (Figure 7) and HER-2 receptor (Figure 8) where all negative. The lesion turned out to be a “triple-negative” carcinoma. Ki67 staining was about 10%.



**Fig. 6.** Negative ER receptor immunohistochemical stain (200X)




**Fig. 7.** Negative PR immunohistochemical stain (200X)



**Fig. 8.** HER-2 receptor status (200X)

Angiosarcoma was ruled out with negative CD31 and CD34 immunohistochemical staining (Figure 9).



**Fig. 9.** Tumor cells negative for CD31 immunohistochemical stain (100X)

## Discussion

Different spindle cell changes were considered in the differential diagnosis.<sup>9</sup> Mild fibromatosis, nodular fasciitis, squamous metaplasia or granulation tissue reaction show less nuclear and cellular atypical features and lower mitotic activity. Low-grade sarcomas ie. fibrosarcoma should not express keratins.<sup>10-15</sup>

The adenomyoepithelioma presents a particularly large diagnostic challenge. This change morphologically may be very similar to FLSpCC and malignant variants of this disease have also been described.<sup>16-20</sup> In most cases of this lesion, the myoepithelial component is the dominant one. Epithelial cells usually form glandular spaces and can show apocrine, sebaceous or squamous metaplasia or can have papillary epithelial proliferation.<sup>20-23</sup> Such changes were not observed in the described case.<sup>23-29</sup>

## Conclusion

FLSpCC is a rare malignancy, however, this diagnosis carries significant clinical consequences. It has a better prognosis compared to other metaplastic breast cancers, as well as a significantly lower percentage of axillary lymph node metastases compared to „classic“ breast cancers, ie invasive ductal carcinoma of no special type or lobular carcinoma. Some authors even propose to distinguish a group of lesions called „breast lesions of limited metastatic potential“ to emphasize a good prognosis in the case of changes such as FLSpCC, low-grade adenosquamous carcinoma or encapsulated papillary carcinoma. On the other hand, due to the risk of underdiagnosis of FLSpCC as a benign lesion, it is recommended that the use of immunohistochemical studies, especially for cytokeratins and SMA, is necessary to properly assess spindle cell changes in the breasts.

## References

1. Benson R, Madan R, Julka PK, Rath GK. Metaplastic carcinoma of breast: A case series of seven patients from a

- tertiary care center and review of literature. *Gulf J Oncolog.* 2016;1(21):74-76.
2. Podetta M, D'Ambrosio G, Ferrari A, et al. Low-grade fibromatosis-like spindle cell metaplastic carcinoma: a basal-like tumor with a favorable clinical outcome. Report of two cases. *Tumori.* 2009;95(2):264-267.
  3. Nonnis R, Paliogiannis P, Giangrande D, Marras V, Trignano M. Low-grade fibromatosis-like spindle cell metaplastic carcinoma of the breast: a case report and literature review. *Clin Breast Cancer.* 2012;12(2):147-150.
  4. Gobbi H, Simpson JF, Borowsky A, Jensen RA, Page DL. Metaplastic breast tumors with a dominant fibromatosis-like phenotype have a high risk of local recurrence. *Cancer* 1999;85(10):2170-2182.
  5. Lee AH. Recent developments in the histological diagnosis of spindle cell carcinoma, fibromatosis and phyllodes tumour of the breast. *Histopathology.* 2008;52(1):45-57.
  6. Luini A, Aguilar M, Gatti G, et al. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. *Breast Cancer Res Treat.* 2007;101(3):349-353.
  7. Rekhi B, Shet TM, Badwe RA, Chinoy RF. Fibromatosis-like carcinoma-an unusual phenotype of a metaplastic breast tumor associated with a micropapilloma. *World J Surg Oncol.* 2007;5:24.
  8. Dwyer JB, Clark BZ. Low-grade fibromatosis-like spindle cell carcinoma of the breast. *Arch Pathol Lab Med.* 2015;139(4):552-557.
  9. Tse GM, Tan PH, Lui PC, Putti TC. Spindle cell lesions of the breast-the pathologic differential diagnosis. *Breast Cancer Res Treat.* 2008;109(2):199-207.
  10. Brogi E. Benign and malignant spindle cell lesions of the breast. *Semin Diagn Pathol.* 2004;21(1):57-64.
  11. Jones M, Fletcher J. Malignant adenomyoepithelioma of the breast. *Pathology.* 2017;49(3):322-325.
  12. Tse GM, Tan PH, Putti TC, et al. Metaplastic carcinoma of the breast: a clinicopathological review. *J Clin Pathol.* 2006;59(10):1079-1083.
  13. Ren W, Guan W, Zhang J, Wang F, Xu G. Pyridoxine 5'-phosphate oxidase is correlated with human breast invasive ductal carcinoma development. *Aging (Albany NY).* 2019;11(7):2151-2176.
  14. Rakha EA, Badve S, Eusebi V, et al. Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management. *Histopathology.* 2016;68(1):45-56.
  15. Sneige N, Yaziji H, Mandavilli SR, et al. Low-grade (fibromatosis-like) spindle cell carcinoma of the breast. *Am J Surg Pathol.* 2001;25(8):1009-1016.
  16. Mikudova V, Rejlekova K, Gyarfas J, et al. Leptomeningeal Metastasis in a Breast Cancer Treated with Two Lines of Intrathecal Chemotherapy - a Case Report. *Klin Onkol.* 2019;32(2):139-142.
  17. Kala C, Athar M, Kala S, et al. Clinical and Cyto-Morphological Characterization of Triple Negative Breast Cancer. *J Cytol.* 2019;36(2):84-88.
  18. Ye C, Wang W, Xia G, et al. A novel curcumin derivative CL-6 exerts antitumor effect in human gastric cancer cells by inducing apoptosis through Hippo-YAP signaling pathway. *Onco Targets Ther.* 2019;12:2259-2269.
  19. Chen J, Chen J, He F, et al. Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA. *Genet Test Mol Biomarkers.* 2019;23(4):264-269.
  20. Soltanian S, Mohamadi N, Rajaei P, Khodami M, Mohammadi M. Phytochemical composition, and cytotoxic, antioxidant, and antibacterial activity of the essential oil and methanol extract of *Semenovia suffruticosa*. *Avicenna J Phytomed.* 2019;9(2):143-152.
  21. Miyamoto K, Minegaki T, Tanahashi M, et al. Synergistic Effects of Olaparib and DNA-damaging Agents in Oesophageal Squamous Cell Carcinoma Cell Lines. *Anticancer Res.* 2019;39(4):1813-1820.
  22. Ge ZC, Qu X, Yu HF, et al. Effect of death decoy receptor 3 on prognosis of breast cancer and function of breast cancer cells in vitro. *Zhonghua Yi Xue Za Zhi.* 2019;99(14):1081-1085.
  23. Jeleń M, Pluta K, Latocha M, et al. Evaluation of angularly condensed diquinothiazines as potential anticancer agents. *Bioorg Chem.* 2019;87:810-820.
  24. Yates JR, Mines MJ, Subramanian PS, et al. Periocular Histiocytoid Carcinoma: Potential Diagnostic Challenges. *Ocul Oncol Pathol.* 2019;5(2):94-101.
  25. Chen Y, Quan R, Bhandari A, et al. Low metallothionein 1M (MT1M) is associated with thyroid cancer cell lines progression. *Am J Transl Res.* 2019;11(3):1760-1770
  26. Zhang Y, Lin P, Zou JY, et al. MiR-216a-5p act as a tumor suppressor, regulating the cell proliferation and metastasis by targeting PAK2 in breast cancer. *Eur Rev Med Pharmacol Sci.* 2019;23(6):2469-2475.
  27. Li PW, Wang HY, Xu LL. Effect of TCF21 on proliferation, migration and vascular production of breast cancer cells. *Zhonghua Bing Li Xue Za Zhi.* 2019;48(4):307-31.
  28. Qian X, Zhang Q, Shao N, et al. Respiratory hyperoxia reverses immunosuppression by regulating myeloid-derived suppressor cells and PD-L1 expression in a triple-negative breast cancer mouse model. *Am J Cancer Res.* 2019;9(3):529-545.
  29. Parvin T, Das C, Choudhury M, Chattopadhyay BK, Mukhopadhyay M. Prognostic Utility of Cyclin D1 in Invasive Breast Carcinoma. *Indian J Surg Oncol.* 2019;10(1):167-173.